U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Inactive Ingredients in Approved Drug Products Search

Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with H

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
182824 Q4 2022 HYDROXYPROPYL CELLULOSE (90000 WAMW) BUCCAL FILM, SOLUBLE 292mg Correction
182825 Q4 2022 HYDROXYPROPYL CELLULOSE (1600000 WAMW) BUCCAL FILM, SOLUBLE 292mg Correction
182826 Q3 2022 HYPROMELLOSE ORAL POWDER, FOR SUSPENSION 150.00 mg Correction
182827 Q4 2022 HYPROMELLOSE ORAL POWDER, FOR SUSPENSION 65.00 mg/ 5.00 ml Correction
182828 Q3 2022 HYPROMELLOSE ORAL SOLUTION 21.90 mg/ 5.00 ml Correction
182829 Q4 2022 HYPROMELLOSE ORAL SOLUTION 3.70 mg/ 1.00 ml Correction
182830 Q3 2022 HYPROMELLOSE ORAL SUSPENSION 1832mg Correction
182831 Q4 2022 HYPROMELLOSE ORAL SUSPENSION 305mg Correction
182832 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE ORAL CAPSULE 89mg Correction
182833 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED ORAL CAPSULE 89mg Correction
182834 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE ORAL CAPSULE, DELAYED RELEASE 104mg Correction
182835 Q4 2022 Hypromellose acetate succinate 12070923 (3 mPa.s) ORAL CAPSULE, DELAYED RELEASE 104mg Correction
182836 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE ORAL CAPSULE, EXTENDED RELEASE 67mg Correction
182837 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED ORAL CAPSULE, EXTENDED RELEASE 67mg Correction
182838 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE ORAL GRANULE 92mg Correction
182839 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED ORAL GRANULE 92mg Correction
182840 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE ORAL TABLET 4480mg Correction
182841 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED ORAL TABLET 4480mg Correction
182842 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE ORAL TABLET, DELAYED RELEASE 2040mg Correction
182843 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED ORAL TABLET, DELAYED RELEASE 2040mg Correction
182844 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE ORAL TABLET, EXTENDED RELEASE 29.00 mg Correction
182845 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED ORAL TABLET, EXTENDED RELEASE 29.00 mg Correction
182846 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE 12070923 (3 MM2/S) ORAL TABLET, DELAYED RELEASE 1800mg Correction
182847 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE 12070923 (3 MPA.S) ORAL TABLET, DELAYED RELEASE 1800mg Correction
182848 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE 16070722 (3 MM2/S) ORAL CAPSULE, DELAYED RELEASE 99mg Correction
182849 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE 16070722 (3 MPA.S) ORAL CAPSULE, DELAYED RELEASE 99mg Correction
182955 Q4 2022 HYPROMELLOSE VAGINAL TABLET, FILM COATED 54.21 mg Deletion
182956 Q4 2022 HYPROMELLOSE 2208 (15000 MPA.S) BUCCAL TABLET, EXTENDED RELEASE 17.25 mg Deletion
182957 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2/S) ORAL CAPSULE, EXTENDED RELEASE 56.55 mg 57mg Deletion
182958 Q4 2022 HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2/S) ORAL TABLET, EXTENDED RELEASE 9.92 mg Deletion
183059 Q3 2022 HEXYLENE GLYCOL TOPICAL GEL 2.00 %w/w MDE Replacement
183060 Q4 2022 HEXYLENE GLYCOL TOPICAL GEL 130mg MDE Replacement
183061 Q3 2022 HIGH DENSITY POLYETHYLENE TRANSDERMAL FILM, EXTENDED RELEASE 85.00 mg MDE Replacement
183062 Q4 2022 HIGH DENSITY POLYETHYLENE TRANSDERMAL FILM, EXTENDED RELEASE 85mg MDE Replacement
183063 Q3 2022 HISTIDINE INTRAVENOUS INJECTABLE, LIPOSOMAL 0.16 %w/v MDE Replacement
183064 Q4 2022 HISTIDINE INTRAVENOUS INJECTABLE, LIPOSOMAL 63mg MDE Replacement
183065 Q3 2022 HYDROCHLORIC ACID INTRAMUSCULAR INJECTION, SOLUTION 1.10 %w/v MDE Replacement
183066 Q4 2022 HYDROCHLORIC ACID INTRAMUSCULAR INJECTION, SOLUTION 8mg MDE Replacement
183067 Q3 2022 HYDROGENATED SOYBEAN PHOSPHATIDYLCHOLINE INTRAVENOUS INJECTABLE, LIPOSOMAL 213.00 mg MDE Replacement
183068 Q4 2022 HYDROGENATED SOYBEAN PHOSPHATIDYLCHOLINE INTRAVENOUS INJECTABLE, LIPOSOMAL 388mg MDE Replacement
183069 Q3 2022 HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) ORAL SOLUTION 7.50 mg/ 1.00 ml MDE Replacement
183070 Q4 2022 HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) ORAL SOLUTION 225mg MDE Replacement
183071 Q3 2022 HYDROXYETHYLPIPERAZINE ETHANE SULFONIC ACID INTRAVENOUS INJECTION 0.41 %w/v MDE Replacement
183072 Q4 2022 HYDROXYETHYLPIPERAZINE ETHANE SULFONIC ACID INTRAVENOUS INJECTION 41mg MDE Replacement
183073 Q3 2022 HYDROXYPROPYL CELLULOSE (110000 WAMW) ORAL TABLET, EXTENDED RELEASE 150.00 mg MDE Replacement
183074 Q4 2022 HYDROXYPROPYL CELLULOSE (110000 WAMW) ORAL TABLET, EXTENDED RELEASE 356mg MDE Replacement
183075 Q3 2022 HYPROMELLOSE 2910 (6 MPA.S) ORAL TABLET, FILM COATED, EXTENDED RELEASE 16.76 mg MDE Replacement
183076 Q4 2022 HYPROMELLOSE 2910 (6 MPA.S) ORAL TABLET, FILM COATED, EXTENDED RELEASE 8mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: October 1, 2022
Database Last Updated: October 19, 2022

Back to Top